Distributors / Reps

Find out how IMDA can help you achieve excellence in specialty sales and marketing.



Meet an IMDA Member - PneumaCare
PneumaCare Ltd.                                                  Year established: 2009

U.S. contact:
Paul Reynard

PneumaCare is a Cambridge, U.K.-based company, developing and marketing revolutionary non-contact, non-invasive respiratory imaging systems. Founded in 2009, the company initially focused on the need for better lung function assessment in children. Since that time, PneumaCare has expanded this focus to include adults in the lung function, ICU and thoracic surgery segments.  

Its flagship product, Thora3DI™, uses the PneumaView™ system operating platform and the PneumaView™3D analysis software to provide clinicians with te first, real-time, non-contact, non-invasive bedside imaging of a patient’s tidal breathing. This output allows the clinician to view the regional chest wall movement contributions and analyze these for unexpected asymmetries due to respiratory-related issues.

Thanks to its mobile design, Thora3DI™ can gather recordable data on seated patients in a clinic or other outpatient setting, or at the patient’s bedside in the hospital.

PneumaCare has embarked on a clinical trial in California on patients with chronic obstructive pulmonary disease. Learn more about PneumaCare – including publications, FAQs, testimonials and more – at

IMDA eNews       8/11/2017

So many fantastic colors. Advise your manufacturer partners to spruce up their devices with some color (e.g., Immortal Blue) or special effects (e.g., pearlescent, glow-in-the-dark, even camouflage). RTP Company, a supplier of thermoplastic compounds, has created the Hueforia offering to help device companies evoke a response and reinforce the brand.

The value of mergers and acquisitions in the medical device field was higher in the second quarter than in any other healthcare subsector, according to research from PwC, reports MD+DI. The value of medical device deals in the quarter was $37.billion, driven in large part by BD’s $25.7 billion purchase of C.R. Bard as well as Cardinal’s $6.1 billion acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business.

Medical devices and cybersecurity. Government-sponsored hackers were seen as the biggest threat to cybersecurity among executives in charge of technology, information, and security at drug and medical device makers, according to the 2017 Cyber Healthcare & Life Sciences Survey from KPMG LLP. The data that hackers are seeking are mostly tied to financial information (69 percent) followed by patents and clinical research (63 percent), the survey of 100 U.S. tech, data, security executives from life sciences companies found.

"Some nations desperately want intellectual property to support local life sciences organizations without incurring R&D costs and challenges," said David Remick, a KPMG partner who works with life sciences companies. 

 "Drug and medical device makers have significant volumes of valuable financial and clinical information," said Life Sciences Advisory Leader Alison Little. "Recent cyber events targeting the life sciences industry demonstrate that market capitalization can be immediately eroded depending on the nature of the cyberattack and extent of damage."

"The life science industry is increasingly engaging patients directly through web portals and apps to help them better manage their conditions, but this opens the door to new risks," said Michael Ebert, a KPMG partner who leads cyber for the Healthcare & Life Sciences Practice